A number of tools are available to assess disease severity and progression in patients with peripheral neuropathies such as CIDP. Gain a better understanding of four of these tools.
University Health Network /Toronto General Hospital Canada
10:32 MIN
MMN
Hear the results of a trial to determine the feasibility of switching patients with multifocal motor neuropathy on intravenous to subcutaneous immunoglobulin.
Duke University Medical Center in Durham, North Carolina
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
CIDP
Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
MMN
Claudia Sommer is a Professor of Neurology at the University of W├╝rzburg, Germany.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
CIDP
GBS
Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan.